Abstract:BackgroundCardiovascular disease remains a major health care challenge. The knowledge about the underlying mechanisms of the respective vascular disease etiologies has greatly expanded over the last decades. This includes the contribution of microRNAs, endogenous non-coding RNA molecules, known to vastly influence gene expression. In addition, short interference RNA has been established as a mechanism to temporarily affect gene expression. This review discusses challenges relating to the design of a RNA interference therapy strategy for the modulation of vascular disease. Despite advances in medical and surgical therapies, atherosclerosis (ATH), aortic aneurysms (AA) are still associated with high morbidity and mortality. In addition, intimal hyperplasia (IH) remains a leading cause of late vein and prosthetic bypass graft failure. Pathomechanisms of all three entities include activation of endothelial cells (EC) and dedifferentiation of vascular smooth muscle cells (VSMC). RNA interference represents a promising technology that may be utilized to silence genes contributing to ATH, AA or IH. Successful RNAi delivery to the vessel wall faces multiple obstacles. These include the challenge of cell specific, targeted delivery of RNAi, anatomical barriers such as basal membrane, elastic laminae in arterial walls, multiple layers of VSMC, as well as adventitial tissues. Another major decision point is the route of delivery and potential methods of transfection. A plethora of transfection reagents and adjuncts have been described with varying efficacies and side effects. Timing and duration of RNAi therapy as well as target gene choice are further relevant aspects that need to be addressed in a temporo-spatial fashion.ConclusionsWhile multiple preclinical studies reported encouraging results of RNAi delivery to the vascular wall, it remains to be seen if a single target can be sufficient to the achieve clinically desirable changes in the injured vascular wall in humans. It might be necessary to achieve simultaneous and/or sequential silencing of multiple, synergistically acting target genes. Some advances in cell specific RNAi delivery have been made, but a reliable vascular cell specific transfection strategy is still missing. Also, off-target effects of RNAi and unwanted effects of transfection agents on gene expression are challenges to be addressed. Close collaborative efforts between clinicians, geneticists, biologists, and chemical and medical engineers will be needed to provide tailored therapeutics for the various types of vascular diseases.

Non-viral Nucleic Acid Therapeutics: Revolutionizing the Landscape of Atherosclerotic Treatment

Nanocarrier-Based Targeting of Cluster of Differentiation 44 for Treating Atherosclerosis: A Review

Targeting noncoding RNAs to treat atherosclerosis

Non-coding RNA-Associated Therapeutic Strategies in Atherosclerosis

Nanocarrier Based Targeting of Vascular Cell Adhesion Molecule-1 for Diagnosis and Treatment of Atherosclerosis: Current Status and Future Perspectives

Targeted Delivery of Nanoparticles to Blood Vessels for the Treatment of Atherosclerosis

Novel RNAi-Based Therapies for Atherosclerosis

RNA interference-based therapies for atherosclerosis: Recent advances and future prospects

Recent advances in inhibiting atherosclerosis and restenosis: from pathogenic factors, therapeutic molecules to nano-delivery strategies

Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms

RNAi therapy to the wall of arteries and veins: anatomical, physiologic, and pharmacological considerations

Current RNA strategies in treating cardiovascular diseases

Nanotechnology-based non-viral vectors for gene delivery in cardiovascular diseases

RNA Therapeutics for the Cardiovascular System

Current targeting strategies and advanced nanoplatforms for atherosclerosis therapy

Small non-coding RNA therapeutics for cardiovascular disease

Advances in Imaging and Treatment of Atherosclerosis Based on Organic Nanoparticles

Nature-inspired nanocarriers for improving drug therapy of atherosclerosis

Advances in the treatment of atherosclerosis with ligand-modified nanocarriers

Atherosclerosis Treatment with Stimuli‐Responsive Nanoagents: Recent Advances and Future Perspectives

Nanomedicine-based drug delivery strategies for the treatment of atherosclerosis